Coverage
-
May 03, 2017
Generic-drug maker Mylan Pharmaceuticals Inc. won't be appealing the Third Circuit's decision affirming a Pennsylvania federal court's dismissal of the company's antitrust suit alleging Warner Chilcott restrained competition for acne medication Doryx, as the deadline for petitioning the U.S. Supreme Court has passed.
14 other articles on this case.
View all »